GPER1 and inclusion body myositis: Given that therapeutic targeting of GPER is currently under preclinical investigation for metabolic disorders and potentially cancer—using the small-molecule GPER agonist G-1 (Tespria) [45,46]—GPER could represent a promising novel target for IBM treatment.